About The Study: In people with inadequately controlled type 2 diabetes treated with basal insulin in this randomized clinical trial with 1,428 participants, weekly tirzepatide compared with prandial insulin as an additional treatment with insulin glargine demonstrated reductions in HbA1c and body weight with less hypoglycemia.
Authors: Julio Rosenstock, M.D., of Velocity Clinical Research at Medical City in Dallas, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.20294)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the European Association for the Study of Diabetes Annual Meeting 2023.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.20294?guestAccessKey=829f6242-2bbd-4685-b1cb-603307c596d0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100323
JAMA